EUVIMEDEUVIMED entdecken
Open Access

ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma

Shreya Budhiraja, Graysen McManus, Shivani Baisiwala, Ella N Perrault, Sia Cho, Miranda Saathoff, Li Chen, Cheol H Park, Hasaan A Kazi, Crismita Dmello, Peiyu Lin, C David James und 3 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Shreya Budhiraja und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Glioblastoma, Drug Resistance, Neoplasm, Brain Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCI NIH HHS, Germany Ministry of Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cellular functions hinge on the meticulous orchestration of protein transport, both spatially and temporally. Central to this process is retrograde trafficking, responsible for targeting proteins to the nucleus. Despite its link to many diseases, the implications of retrograde trafficking in glioblastoma (GBM) are still unclear.

Methods

To identify genetic drivers of TMZ resistance, we conducted comprehensive CRISPR-knockout screening, revealing ADP-ribosylation factor 4 (ARF4), a regulator of retrograde trafficking, as a major contributor.

Results

Suppressing ARF4 significantly enhanced TMZ sensitivity in GBM patient-derived xenograft (PDX) models, leading to improved survival rates (P < .01) in both primary and recurrent lines. We also observed that TMZ exposure stimulates ARF4-mediated retrograde trafficking. Proteomics analysis of GBM cells with varying levels of ARF4 unveiled the influence of this pathway on EGFR signaling, with increased nuclear trafficking of EGFR observed in cells with ARF4 overexpression and TMZ treatment. Additionally, spatially resolved RNA-sequencing of GBM patient tissues revealed substantial correlations between ARF4 and crucial nuclear EGFR (nEGFR) downstream targets, such as MYC, STAT1, and DNA-PK. Decreased activity of DNA-PK, a DNA repair protein downstream of nEGFR signaling that contributes to TMZ resistance, was observed in cells with suppressed ARF4 levels. Notably, treatment with DNA-PK inhibitor, KU-57788, in mice with a recurrent PDX line resulted in prolonged survival (P < .01), highlighting the promising therapeutic implications of targeting proteins reliant on ARF4-mediated retrograde trafficking.

Conclusions

Our findings demonstrate that ARF4-mediated retrograde trafficking contributes to the development of TMZ resistance, cementing this pathway as a viable strategy to overcome chemoresistance in GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaDrug Resistance, NeoplasmBrain NeoplasmsXenograft Model Antitumor AssaysADP-Ribosylation FactorsHumansAnimalsMiceTemozolomideAntineoplastic Agents, AlkylatingProtein TransportTumor Cells, CulturedErbB ReceptorsCell ProliferationCell Line, TumorSignal TransductionGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

ARF4chemoresistanceglioblastomaretrograde traffickingwhole-genome CRISPR screen

Substanzen

ADP-Ribosylation FactorsARF4 protein, humanTemozolomideAntineoplastic Agents, AlkylatingErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Department of Neurobiology, Northwestern University, Evanston, Illinois, USA.
  • Microenvironment and Immunology Research Laboratory, Medical Center - University of Freiburg, Freiburg, Germany.
  • Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany.
  • Faculty of Medicine, University of Freiburg, Freiburg, Germany.

ORCID-Profile: Atique U Ahmed

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • Germany Ministry of Education and Research
  • SPORE for Translational Approaches to Brain Cancer
  • The Else Kröner-Fresenius Foundation and MEPHISTO

Zitieren

APA

Budhiraja, S., McManus, G., Baisiwala, S., Perrault, E. N., Cho, S., Saathoff, M., Chen, L., Park, C. H., Kazi, H. A., Dmello, C., Lin, P., James, C. D., Sonabend, A. M., Heiland, D. H., & Ahmed, A. U. (2024). ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae059

Vancouver

Budhiraja S, McManus G, Baisiwala S, Perrault EN, Cho S, Saathoff M, et al. ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae059

BibTeX
@article{Budhiraja2024,
  author = {Budhiraja, Shreya and McManus, Graysen and Baisiwala, Shivani and Perrault, Ella N and Cho, Sia and Saathoff, Miranda and Chen, Li and Park, Cheol H and Kazi, Hasaan A and Dmello, Crismita and Lin, Peiyu and James, C David and Sonabend, Adam M and Heiland, Dieter H and Ahmed, Atique U},
  title = {ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae059}
}
Kostenlos starten →